Physician

Ammar Al-Obaidi

According to 2025 Medicare claims, Ammar Al-Obaidi (NPI: 1437643269) practices internal medicine in the Wichita, KS market, with the plurality of this provider's patient population coming from Sedgwick, KS. This provider's primary affiliated billing organization is CANCER CENTER OF KANSAS, P.A. (NPI: 1841251394; TIN: 481181579) and primary practice location at 67214-3728. Al-Obaidi is affiliated with the Vytalize Health KS 25 LLC (ACO ID: A5671), participating under the MSSP model.

Al-Obaidi's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 580 traditional Medicare patients, billed 158,460 HCPCS/CPT codes, and received $2,660,092 in Medicare payments. The top billing code was 96413 (Administration of chemotherapy into vein, 1 hour or less). Part D data shows 183 prescription claims across 52 beneficiaries totaling $322,267 in drug costs, led by Ondansetron Hcl (Ondansetron Hcl). Open Payments data shows 54 records totaling $1,218. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider has fewer than 5 years of reported Medicare Part B carrier billing data, so a reliable trend cannot be assigned. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $2,454 to $322,267. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Part B Carrier Billing Trend. X-axis: year 2015-2024. Y-axis: Medicare payment, unit: USD. Field: Tot_Mdcr_Pymt_Amt. Source: Medicare Physician & Other Practitioners by Provider.0$1.3M$2.7M2024 Medicare payment: $2,660,092 (USD; Tot_Mdcr_Pymt_Amt)2015201620172018201920202021202220232024
YearPatientsClm LinesPayment
2015N/RN/RN/R
2016N/RN/RN/R
2017N/RN/RN/R
2018N/RN/RN/R
2019N/RN/RN/R
2020N/RN/RN/R
2021N/RN/RN/R
2022N/RN/RN/R
2023N/RN/RN/R
2024580158,460$2,660,092

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Part D Events Trend. X-axis: year 2015-2024. Y-axis: Drug cost, unit: USD. Field: Tot_Drug_Cst. Source: Medicare Part D Prescribers by Provider.0$272K$544K2018 Drug cost: $2,454 (USD; Tot_Drug_Cst)2019 Drug cost: $8,678 (USD; Tot_Drug_Cst)2020 Drug cost: $17,336 (USD; Tot_Drug_Cst)2021 Drug cost: $31,417 (USD; Tot_Drug_Cst)2022 Drug cost: $544,157 (USD; Tot_Drug_Cst)2023 Drug cost: $38,550 (USD; Tot_Drug_Cst)2024 Drug cost: $322,267 (USD; Tot_Drug_Cst)2015201620172018201920202021202220232024
YearPatientsClaimsDrug Cost
2015N/RN/RN/R
2016N/RN/RN/R
2017N/RN/RN/R
20181633$2,454
20191860$8,678
202029149$17,336
202132115$31,417
202221114$544,157
20232290$38,550
202452183$322,267

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

CodeDescriptionPatientsClm LinesTotal Payment
96413Administration of chemotherapy into vein, 1 hour or less206323$92
96367Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less129301$20
96375Injection of additional new drug or substance into vein83139$11
96372Injection of drug or substance under skin or into muscle184290$10
J1100Injection, dexamethasone sodium phosphate, 1 mg1191,923$0

Top 5 Part D drugs in 2024

By total drug costs.

DrugGenericClaimsTotal Day SupplyTotal Drug Cost
Ondansetron HclOndansetron Hcl18546$2,454
Prochlorperazine MaleateProchlorperazine Maleate17621$490
AnastrozoleAnastrozole211,240$170
PrednisonePrednisone20533$87

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

CategoryDefinitionRecordsTotal Reported AmountTop Related Entity
General PaymentsReported payment or transfer-of-value amount.54$1,218Stemline Therapeutics Inc.
Research PaymentsReported research-related payment or transfer-of-value amount.0$0N/R
Ownership / Investment InterestsReported value of ownership or investment interests.0$0N/R

FAQ

What Medicare data is available for Ammar Al-Obaidi?

Tedicare shows public-source Medicare data for Ammar Al-Obaidi (NPI 1437643269), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Ammar Al-Obaidi have ACO affiliation data?

Ammar Al-Obaidi is shown with ACO affiliation data for Vytalize Health KS 25 LLC (MSSP, ACO ID A5671).

What billing organization is linked to Ammar Al-Obaidi?

Ammar Al-Obaidi is linked to CANCER CENTER OF KANSAS, P.A. (billing NPI 1841251394) in the available physician profile data.

Does Ammar Al-Obaidi have Open Payments data?

Ammar Al-Obaidi has 54 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.